CYGNOS BIOTECH, LLC
CYGNOS BIOTECH, LLC is a federal contractor, registered under UEI PXYDY5CQJDM3 and CAGE code 8WQ76. It has been awarded $1,601,657 across 2 federal contracts. Primary work spans Research and Development in Biotechnology (except Nanobiotechnology). Top awarding agencies include Department Of Defense.
Contact Information
Registration and classification details
Registration
UEI Code
PXYDY5CQJDM3CAGE Code
8WQ76Entity Structure
Partnership or Limited Liability PartnershipEstablished
N/ABusiness Classifications
NAICS Codes
Federal Contracting Overview
Award totals, agency breakdown, NAICS distribution, and geographic footprint.
AI Capability Profile
CYGNOS BIOTECH, LLC specializes in pioneering research and development of broad-spectrum antiviral therapeutics targeting host-pathogen interactions, with a focus on agnostic drug platforms designed to enhance host resilience against diverse viral pathogens. Their technical expertise lies in molecul...
CYGNOS BIOTECH, LLC specializes in pioneering research and development of broad-spectrum antiviral therapeutics targeting host-pathogen interactions, with a focus on agnostic drug platforms designed to enhance host resilience against diverse viral pathogens. Their technical expertise lies in molecular virology, host-directed therapeutics, and systems biology approaches to identify conserved cellular pathways exploitable for antiviral intervention. The company differentiates itself through its focus on host-targeted strategies rather than pathogen-specific inhibition, enabling potential efficacy against emerging and re-emerging viral threats without requiring strain-specific redesign. This approach leverages advanced pharmacological screening, functional genomics, and protein interaction mapping to uncover druggable host factors critical for viral replication. The contractor has demonstrated direct engagement with the Department of Defense, delivering defense-relevant biotechnological solutions aimed at enhancing force readiness against biological threats. Their work supports military medical research priorities, particularly in pandemic preparedness and countering bioengineered pathogens through novel therapeutic platforms. This relationship reflects a strategic alignment with DoD’s biodefense and medical innovation objectives. CYGNOS BIOTECH operates primarily within NAICS 541714, which encompasses non-nanobiotechnology biopharmaceutical R&D focused on therapeutic discovery and preclinical development. The company’s market positioning centers on high-risk, high-reward host-targeted antiviral platforms, distinguishing it from conventional vaccine or monoclonal antibody developers. They occupy a niche in next-generation antiviral innovation, targeting unmet needs in pandemic response and biodefense. As a small business entity structured under 2K classification, CYGNOS BIOTECH is privately held with no federal certifications on record. Based in Miami, Florida, the company maintains a focused, research-driven footprint within the U.S. government’s biomedical R&D ecosystem, positioning itself as a specialized innovator in therapeutic biotechnology for national security and public health applications.
Key Performance Metrics
Awards Count
All time
Active
Currently performing
Completed
Past period of performance
Total Awards
All time
Contracts
Prime · all time
Subcontracts
Sub · all time
Grants
Prime · all time
Subgrants
Sub · all time
